Story perspectives

Eli Lilly to Seek Retatrutide Approval After 22% Weight Loss

7/23/2026

Summary

Story summary

Eli Lilly will file for retatrutide approval in Q1 2027.
Phase 3 trials showed adults with obesity and diabetes lost 20.8% of weight after 80 weeks, while a study in adults with severe obesity and cardiovascular disease reported a 22.6% loss.
Both studies noted better blood-sugar control and common side effects of diarrhea, nausea and constipation.
Analysts project retatrutide could generate $3.8 billion in 2030 sales within a $100 billion market by the 2030s.

1 of 1

Story summary

Eli Lilly will file for retatrutide approval in Q1 2027.
Phase 3 trials showed adults with obesity and diabetes lost 20.8% of weight after 80 weeks, while a study in adults with severe obesity and cardiovascular disease reported a 22.6% loss.
Both studies noted better blood-sugar control and common side effects of diarrhea, nausea and constipation.
Analysts project retatrutide could generate $3.8 billion in 2030 sales within a $100 billion market by the 2030s.